目的 探討愈風寧心滴丸聯(lián)合曲美他嗪治療冠心病的臨床效果。方法 選取2015年8月-2017年12月北京市東城區(qū)第一人民醫(yī)院收治的92例冠心病患者，隨機分為對照組和治療組，每組各46例。對照組口服鹽酸曲美他嗪片，1片/次，3次/d。治療組在對照組基礎上口服愈風寧心滴丸，15丸/次，3次/d。兩組均連續(xù)治療4周。觀察兩組的中醫(yī)證候療效和心電圖療效，比較兩組治療前后主要中醫(yī)癥候、低/高密度脂蛋白膽固醇（LDL-C/HDL-C）、紅細胞沉降率（ESR）、相鄰心率間期差>50 ms的個數(shù)占總心跳次數(shù)的百分比（PNN50）、RR間期總體標準差（SDNN）、C反應蛋白（CRP）、同型半胱氨酸（Hcy）、中性粒細胞（N）/淋巴細胞（L）比值（NLR）的變化情況。結果 治療后，對照組和治療組中醫(yī)證候療效分別為78.26%、93.48%，心電圖療效分別為71.74%、89.13%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組各項中醫(yī)癥候積分及總分、LDL-C/HDL-C、ESR值、CRP、Hcy、外周血NLR值較治療前均顯著降低，但PNN50、SDNN值均顯著增加，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；治療后，治療組各項中醫(yī)癥候積分及總分、LDL-C/HDL-C、ESR值、CRP、Hcy、外周血NLR值均顯著低于對照組，但PNN50、SDNN值顯著高于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 愈風寧心滴丸聯(lián)合曲美他嗪治療冠心病具有較好的臨床療效，可有效緩解患者癥狀，改善血脂代謝和心臟自主神經(jīng)功能，改善機體免疫炎癥狀態(tài)，具有一定的臨床推廣應用價值。

Objective To investigate the clinical effects of Yufeng Ningxin Dripping Pills combined with trimetazidine in treatment of coronary heart disease. Methods Patients (92 cases) with coronary heart disease in the First People's Hospital of Dongcheng District in Beijing from August 2015 to December 2017 were randomly divided into control (46 cases) and treatment (46 cases) groups. Patients in the control group were po administered with Trimetazidine Dihydrochloride Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Yufeng Ningxin Dripping Pills on the basis of the control group, 15 pills/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the TCM syndrome efficacy and electrocardiogram efficacy were evaluated, and TCM symptoms score, LDL-C/HDL-C, ESR, PNN50, RR, SDNN, CRP, Hcy, and NLR in two groups before and after treatment were compared. Results After treatment, the TCM syndrome efficacy in the control group were 78.26% and 93.48%, and electrocardiogram efficacy in two groups were 71.74% and 89.13%, and there were differences between two groups (P<0.05). After treatment, the scores and total scores of various TCM syndromes, LDL-C/HDL-C, ESR, CRP, Hcy, and NLR in two groups were significantly decreased, but PNN50 and SDNN were significantly increased, and there were differences in the same group (P<0.05). After treatment, total scores of various TCM syndromes, LDL-C/HDL-C, ESR, CRP, Hcy, and NLR in the treatment group were lower than those in the control group, but PNN50 and SDNN in the treatment group were higher than those in the control group, and there were differences between two groups (P<0.05). Conclusion Yufeng Ningxin Dripping Pills combined with trimetazidine has significant clinical effect in treatment of coronary heart disease, and can effectively alleviate symptoms, and can improve blood lipid metabolism and cardiac autonomic nervous function, and also can improve the immune inflammatory state of the body, which has a certain clinical application value.